DENVER, Colo., Nov 2, 2023 (www.247marketnews.com)- Panbela Therapeutics Inc (NASDAQ: PBLA) stated, this morning, that it published preclinical and clinical data from studies of CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in recent onset type 1 diabetes (T1D), showing that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.
Panbela Therapeutics is trading at $1.12, up $0.323 (+40.62%), on 3.18M premarket shares traded.
Its 52-week range is $0.70 to $295.20. It hit a new 52-week low last week and this looks like it may be a potential trend reversal.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.